Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty

91Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective: To investigate longitudinally body mass index (BMI) evolution and obesity prevalence in a large and very homogeneous study population consisting only of girls with non-organic central precocious puberty (CPP) who were treated with gonadotropin-releasing hormone agonists (GnRHa) for at least two years. Patients and design: The 101 girls with idiopathic CPP who were selected for this study fulfilled the following inclusion criteria: (a) suppression of gonadotropin and gonadal sex steroid secretion during the overall GnRHa treatment period; (b) adequate compliance with the therapy regimen. All the girls were treated for 44±14 months and were followed-up for 15.7±7.8 months after therapy withdrawal. Results: At the start of therapy, 23.8% of the girls had a BMI exceeding 2 standard deviation scores (SDS) and were therefore classified as obese; both average BMI-SDS and obesity prevalence significantly decreased during the treatment period (X2 = 16.6, P < 0.0005) and only 4% of the patients, all with pre-existing obesity, were still obese at the end of therapy; during the therapy period, BMI-SDS increased in none of the patients. Both average BMI-SDS and obesity prevalence (from 4 to 0%; X2 = 4.0, P < 0.05) further decreased during the period that followed therapy withdrawal. Conclusions: (a) girls with idiopathic CPP are frequently obese at the onset of GnRHa therapy (23.8%), probably due to the hormonal changes which accompany the start of puberty; (b) their obesity is neither long-lasting nor related to GnRHa administration; (c) on the contrary, GnRHa therapy may have a favourable effect on BMI decrease, provided that treatment is performed for at least two years and is accompanied by a complete suppression of gonadotropin secretion; (d) this unexpected effect, which has never been reported hitherto, might represent a further indication for GnRHa administration in idiopathic CPP. © 2004 Society of the European Journal of Endocrinology.

Cite

CITATION STYLE

APA

Arrigo, T., De Luca, F., Antoniazzi, F., Galluzzi, F., Segni, M., Rosano, M., … Lombardo, F. (2004). Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. European Journal of Endocrinology, 150(4), 533–537. https://doi.org/10.1530/eje.0.1500533

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free